Novartis will be presenting positive phase III data results on November 9 from ACZ885, a fully human monoclonal antibody that inhibits IL-1 beta at the American College of Rheumatology‘s (ACR) Annual Scientific Meeting in Chicago, US.

It was suggested by the study that 45 per cent of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001).

“These data demonstrate the significant benefits that ACZ885 may provide this young population, both in steroid reduction and in extending the period these children can live free from SJIA flares,” said David Epstein, Head of the Pharmaceuticals Division of Novartis. “Novartis is committed to helping improve the health of patients with SJIA and other inflammatory diseases, which is why we are delighted to be sharing these results.”